Adicet bio reports positive data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced positive safety and efficacy data from the company's ongoing phase 1 study of adi-001 for the potential treatment of relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl). “these data are exciting and beyond what one might expect to see given that patients enrolled in.
ACET Ratings Summary
ACET Quant Ranking